摘要
肿瘤免疫治疗,尤其是免疫检查点抑制剂(immune checkpoint inhibitor,ICI)的出现为晚期非小细胞肺癌的治疗提供了新思路。精准地评价治疗效果能指导临床决策,在肿瘤患者治疗过程中至关重要。正电子发射体层成像(positron emission tomography,PET)/计算机体层成像(computed tomography,CT)作为一种非侵入性、高安全性的全身影像学检查方法,能提供肿瘤原发灶的代谢情况、淋巴结转移和远处转移等信息,已被广泛用于肿瘤的诊断与疗效评价。与此同时,新型靶向显像剂正逐步进入临床试验阶段,将有利于对免疫治疗效果的精准评估。本文将对PET/CT评价肿瘤免疫治疗(以ICI为主)效果的临床应用和研究进展进行述评。
The development of tumor immunotherapy,especially immune checkpoint inhibitors,has provided new ways for the treatment of advanced non-small cell lung cancer.Accurate evaluation of therapeutic efficacy can guide clinical decision making and is critical in the treatment of oncology patients.Positron emission tomography(PET)/computed tomography(CT),as a noninvasive and high-safety whole-body imaging examination,can provide information on metabolism of primary lesions,lymph nodes and metastasis,and has been widely used in the diagnosis and evaluation of tumor treatment efficacy.Meanwhile,novel targeting agents are gradually entering the clinical trials,which will improve the accuracy of treatment evaluation.This review summarized the clinical application and research progress of PET/CT in evaluating the efficacy of immunotherapy(mainly ICI).
作者
李林蔚
杨健
陈跃
LI Linwei;YANG Jian;CHEN Yue(Department of Nuclear Medicine,The Affiliated Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province,China;Institute of Nuclear Medicine,Southwest Medical University,Luzhou 646000,Sichuan Province,China;Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province,Luzhou 646000,Sichuan Province,China;Sichuan Province Quality Control Center of Nuclear Medicie,Luzhou 646000,Sichuan Province,China)
出处
《肿瘤影像学》
2023年第2期114-121,共8页
Oncoradiology
基金
泸州市人民政府西南医科大学科技战略合作项目任务书(2021LZXNYD-P03)
四川省卫生健康委员会医学科技项目(21ZD005)。
